GENENTECH, INC.
SOUTH SAN FRANCISCO, CA



Located in South San Francisco, California, Genentech, Inc. is a renowned biotechnology company that's been at the forefront of innovation for over forty years. Today, it operates as part of the Roche Group, continuing its tradition of pioneering research and development in cutting-edge medicines for serious medical conditions. Since merging with Roche in 2009, Genentech has made significant contributions both to healthcare and corporate culture. Known for a portfolio rich in both market-tested products and promising research pipelines, Genentech remains dedicated to addressing immediate needs while pushing the boundaries of future innovation. It plays a vital role within Roche, housing its U.S. pharmaceutical headquarters at its South San Francisco campus. Here, Genentech Research and Early Development functions as an independent unit, preserving the spirit of daring exploration and maintaining high ethical standards. The company’s roots trace back to 1976, when founders Herb Boyer and Bob Swanson kicked off what would become a legendary entity in biotech over an informal gathering. This legacy is marked by prestigious recognitions, such as being named one of FORTUNE magazine's '100 Best Companies to Work For' for two decades straight. Genentech also ranks second on Nature Index's list of top 100 corporations by scientific output between 2012 and 2016 – a testament to its commitment to excellence. Renowned for fostering an inclusive and diverse workplace, the company is recognized by Science Careers as one of 'The Top Twenty Employers' for numerous years. Its consistent perfect scores on the Human Rights Campaign Foundation's Corporate Equality Index highlight Genentech’s emphasis on respect and equality within its teams. Furthermore, it earns spots in Fortune's '100 Best Workplaces for Women' and Working Mother magazine’s 'Top 100 Companies for Working Mothers,' showcasing its supportive policies promoting a balanced work environment. Beyond being an employer of choice, Genentech is also recognized for its philanthropic efforts, topping the San Francisco Business Times list as one of the leading bay area corporate donors. Though incorporated in Delaware and having a wide-reaching influence both nationally and internationally, its headquarters remains central to Southern California. Through visionary leadership and a commitment to health impact around the globe, Genentech continues to be a powerful force in biotech innovation and corporate responsibility.

KEY FACTS ABOUT GENENTECH, INC.

Company name
GENENTECH, INC.
Status
Active
Filed Number
P25895
FEI Number
942347624
Date of Incorporation
September 5, 1989
Age - 37 years
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
https://genentech.com
Phones
(888) 835-2555
(650) 225-4630
(800) 334-0290
(800) 821-8590
(888) 662-6728
(844) 287-3783
(650) 225-1000
(800) 626-3553
(650) 225-6000
(503) 992-3600
(760) 231-2440
(707) 454-1000
(502) 995-4600
(866) 411-4266
(650) 225-2580
(650) 225-2500
(800) 551-2231
(877) 436-3683
(866) 422-2377
(800) 530-3083
(650) 467-6800
(650) 225-5566
(650) 225-8326

GENENTECH, INC. NEAR ME

Principal Address
1 DNA Way,
South San Francisco,
CA,
94080,
US
Mailing Address
Attn: Corporate Legal Department,
1 DNA Way,
South San Francisco,
CA,
94080,
US

See Also

Officers and Directors

The GENENTECH, INC. managed by the three persons from South San Francisco on following positions: Director, Asst, CEO,

Akiko Iwasaki

Position
Director Active
From
South San Francisco, CA, CA

Anjna Mehta

Position
Asst Active
From
South San Francisco, CA, CA

Ashley Magargee

Position
CEO, Active
From
South San Francisco, CA, CA





Registered Agent is CORPORATION SERVICE COMPANY

Address
1201 HAYES STREET, TALLAHASSEE, FL, 32301, 2525

Events

November 6, 2009
CANCEL ADM DISS/REV
September 25, 2009
REVOKED FOR ANNUAL REPORT
April 2, 1996
REINSTATEMENT
August 25, 1995
REVOKED FOR ANNUAL REPORT
November 16, 1993
REINSTATEMENT
August 13, 1993
REVOKED FOR ANNUAL REPORT

Annual Reports

2025
January 21, 2025
2024
March 7, 2024